XML 56 R47.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT REPORTING (Details) - USD ($)
 3 Months Ended 6 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Research and development $ 294,318 $ 261,486 $ 818,686 $ 702,115
General and administrative 521,423 958,375 1,256,781 1,709,228
Cash used in operating activities     (3,373,654) (3,962,095)
Operating Segments [Member]        
Segment Reporting Information [Line Items]        
Research and development [1] 512,000 262,000 1,036,000 702,000
General and administrative [2] 739,000 958,000 1,475,000 1,709,000
Cash used in operating activities [3] $ 1,657,000 $ 2,214,000 $ 3,372,000 $ 3,962,000
[1] Research and development expenses primarily include costs related to laboratory operations, clinical trial execution, investigational device testing, design iterations, and personnel expenses associated with research activities. These costs are recorded within payroll, professional fees, and general and administrative (“G&A”) expense on the face of the statements of operations, as the Company does not maintain a separate R&D line item.
[2] General and administrative expenses encompass overhead, administrative costs associated with clinical trial operations, and certain manufacturing-related costs. R&D costs are included within these categories for financial reporting purposes and are not separately reclassified
[3] Cash used in operating activities is the key internal performance metric tracked by the CODM to evaluate development progress, cash needs, and investment strategy in the absence of commercial revenue.